Our Core Research Team
We are twelve independent laboratories working together to find new ways to prevent cancers, better treat cancers and understand how they arise.
DNA Damage Repair Biology
Cellular Aging Biology
Anti-Cancer Clinical Trials
Cancer Exposome Science
Dr. Nizar Bahlis
Short Bio Summary
Dr. Bahlis is a practising haematologist at the Tom Baker Cancer Centre and an associate professor at the
Arnie Charbonneau Cancer Institute. He obtained his MD from the French Faculty of Medicine
(FFM-Lebanon) in 1995 and completed his medicine and hematology /oncology training at the State
University of NY in Syracuse and the University of Miami. He also completed a post-doctoral research
fellowship in cancer research under the mentorship of Dr Lawrence Boise.
Multiple myeloma (MM) is a hematological malignancy where plasma cells become cancerous. Aiming to improve the outcomes of patients affected by this disease, we have established a Myeloma Genome Sequencing Unit with the goal to identify novel druggable genomic alterations and unmask the mechanisms of drug resistance.
We are also studying genomic instability in this disease, in particular the role of the proteasome-ubiquitin pathway in DNA damage repair. The human DNA damage response is reliant upon signalling using the small modifier protein called Ubiquitin (Ub). Since Ub is recycled by the proteasome, proteasome inhibitors (PI) have the effect of depleting free Ub pools such that the DNA damage-induced Ub-mediated signalling fails. We have found that MM displays a particular sensitivity to PI in combination
with PARP inhibitors, and we are examining the molecular mechanisms underlying this effect.